Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within
the cell, which is responsible for degrading or breaking down a wide variety of proteins.
Carfilzomib has not been approved by the FDA.
Rituximab and dexamethasone are often used to treat Waldenstrom's Macroglobulinemia (WM),
alone or in combination with other drugs. Combinations with rituximab, dexamethasone and
proteasome inhibitors, like carfilzomib, show high levels of activity in WM patients.
In this research study, the investigators are testing the safety and efficacy of Carfilzomib
when used along with Rituximab and Dexamethasone as a possible treatment for Waldenstrom's
Macroglobulinemia.